Get the Stockscreener App
291.49
0.27%
-0.78
After Hours:
289.00
-2.49
-0.85%
Insulet Corporation stock is traded at $291.49, with a volume of 373.31K.
It is down -0.27% in the last 24 hours and down -6.90% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$292.27
Open:
$292.61
24h Volume:
373.31K
Relative Volume:
0.47
Market Cap:
$20.51B
Revenue:
$2.20B
Net Income/Loss:
$402.20M
P/E Ratio:
52.43
EPS:
5.56
Net Cash Flow:
$280.80M
1W Performance:
+2.07%
1M Performance:
-6.90%
6M Performance:
+5.19%
1Y Performance:
+51.95%
1-Day Range:
$289.85
$293.00
1-Week Range:
$284.00
$294.11
52-Week Range:
$173.00
$329.33
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
291.49 | 20.57B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
128.01 | 219.83B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.47 | 156.58B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
400.57 | 153.13B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.44 | 117.84B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.47 | 46.04B | 5.69B | 4.15B | 623.10M | 6.95 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Why Insulet Corporation stock attracts strong analyst attentionFundamental + Technical Hybrid Stock Tips Shared - metal.it
What catalysts could drive Insulet Corporation stock higher in 2025Low Risk Alerts Backed By Experts - jammulinksnews.com
Insulet Corporation Sees Spike in Bullish Option FlowTechnical Stock Breakout Predictions Signal Entry Points - metal.it
How does Insulet Corporation compare to its industry peersPost Market Guidance With High Returns - jammulinksnews.com
What institutional investors are buying Insulet Corporation stockExceptional stock performance - jammulinksnews.com
What are the latest earnings results for Insulet CorporationTrack top-performing stocks in real-time - jammulinksnews.com
What are the technical indicators suggesting about Insulet CorporationFree Real-Time Stock Data - jammulinksnews.com
Why is Insulet Corporation stock attracting strong analyst attentionUnstoppable profit momentum - jammulinksnews.com
What is the dividend policy of Insulet Corporation stockUnlock the power of real-time market data - jammulinksnews.com
What analysts say about Insulet Corporation stockFree Wealth Planning Blueprint - PrintWeekIndia
What to Expect From Insulet's Q2 2025 Earnings Report - MSN
Is Insulet Corporation stock overhyped or has real potentialTremendous gains - jammulinksnews.com
Is Insulet Corporation a good long term investmentRapid wealth accumulation - PrintWeekIndia
What institutions are buying Insulet Corporation stock nowExplosive portfolio gains - jammulinksnews.com
Insulet Corporation Q2 2025 Earnings Preview: Anticipating Significant GrowthNews and Statistics - IndexBox
What To Expect From Insulet's Q2 2025 Earnings Report - Barchart.com
Tubeless Insulin Pumps Market Attracts Startups Amid Booming - openPR.com
Insulin Pumps Market Outlook Report 2025, with Leading - GlobeNewswire
EOFlow’s 'EOPatch' Sales Banned in Europe - Businesskorea
Insulet granted EU-wide injunction against EOFlow in default decision by UPC - MLex
Insulin Pumps Market Outlook Report 2025, with Leading Player Profiles for Medtronic, Insulet, Tandem Diabetes Care, and More - Yahoo.co
What drives Insulet Corporation stock priceTriple-digit wealth increases - jammulinksnews.com
Insulet Corporation Stock Analysis and ForecastFree Wealth Management Insights - jammulinksnews.com
Digital Diabetes Management Market is projected to reach US$ - openPR.com
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):